Effect of intravenous fluid volume on biomarkers of endothelial glycocalyx shedding and inflammation during initial resuscitation of sepsis

Intensive Care Medicine Experimental

Table 2 Fluid and vasopressor use

	Usual care N = 46	Restricted volume N = 49	P value
Fluid volume
T0–T6 (ml) total	1685 (1017, 2500)	1000 (625, 1458)	< 0.001
T0–T6/kg (ml)	23 (15, 33)	12 (7, 20)	< 0.001
Total prerandomisation-T6	3000 (2550, 3900)	2400 (1860, 2750)	< 0.001
Total to T6/kg (ml)	43 (35, 49)	31 (23, 39)	< 0.001
T6–T24 (ml)	1060 (428, 2166)	1145 (500, 2000)	0.84
Total prerandomisation-T24 (ml)	4360 (3350, 5252)	3550 (2750, 4410)	0.008
Total to T24/kg (ml)	61 (46, 79)	40 (31, 64)	0.005
Vasopressor use N (%)	26 (53)	39 (78)
Vasopressor in ED N (%)	23 (50)	36 (73)	0.018
Vasopressor at 24 h N	19 (41)	24 (49)	0.45
Time to start vasopressor (mins):
From ED arrival	250 (168, 483)	223 (127, 316)	0.12
From randomisation	150 (63, 224)	34 (15, 88)	0.001
Type of vasopressor:
Noradrenaline N (%)	23 (50)	30 (60)	0.33
Metaraminol only N (%)	3 (6)	9 (18)
Volume prior to vasopressor (ml)	2000 (2000, 2777)	1400 (1000, 1700)	< 0.001
Duration of vasopressor (h)	33 (15, 50)	21 (9, 42)	0.13
Peak vasopressor dose	0.18 (0.1, 0.43)	0.11 (0.08, 0.22)	0.14
Mean MAP T0–T6 (mmHg)	71 ± 6	73 ± 6	0.21

Data are medians (Q1, Q3) unless stated otherwise. P values calculated using Wilcoxon rank-sum test for continuous variables and Fishers exact test for categorical variables. Peak vasopressor dose mcg/kg/min of noradrenaline (or equivalent)